BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

721 related articles for article (PubMed ID: 19836388)

  • 1. Epigenetics and cancer treatment.
    Kristensen LS; Nielsen HM; Hansen LL
    Eur J Pharmacol; 2009 Dec; 625(1-3):131-42. PubMed ID: 19836388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic alterations and cancer: new targets for therapy.
    Allen A
    IDrugs; 2007 Oct; 10(10):709-12. PubMed ID: 17899489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic changes in cancer.
    Grønbaek K; Hother C; Jones PA
    APMIS; 2007 Oct; 115(10):1039-59. PubMed ID: 18042143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors.
    Schneider-Stock R; Ocker M
    IDrugs; 2007 Aug; 10(8):557-61. PubMed ID: 17665331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead.
    Mai A; Altucci L
    Int J Biochem Cell Biol; 2009 Jan; 41(1):199-213. PubMed ID: 18790076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Innovative approaches to the clinical development of DNA methylation inhibitors as epigenetic remodeling drugs.
    Murgo AJ
    Semin Oncol; 2005 Oct; 32(5):458-64. PubMed ID: 16210086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic changes in prostate cancer: implication for diagnosis and treatment.
    Li LC; Carroll PR; Dahiya R
    J Natl Cancer Inst; 2005 Jan; 97(2):103-15. PubMed ID: 15657340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
    Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA demethylating agents and epigenetic therapy of cancer.
    Mani S; Herceg Z
    Adv Genet; 2010; 70():327-40. PubMed ID: 20920754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker.
    Teodoridis JM; Strathdee G; Brown R
    Drug Resist Updat; 2004; 7(4-5):267-78. PubMed ID: 15533764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
    Zhong S; Fields CR; Su N; Pan YX; Robertson KD
    Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of gene silencing as a therapeutic target for cancer--roles for DNA methylation and its interdigitation with chromatin.
    Baylin SB
    Novartis Found Symp; 2004; 259():226-33; discussion 234-7, 285-8. PubMed ID: 15171257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenome: a new target in cancer therapy.
    Giacinti L; Vici P; Lopez M
    Clin Ter; 2008; 159(5):347-60. PubMed ID: 18998037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic gene regulation in cancer.
    Ballestar E; Esteller M
    Adv Genet; 2008; 61():247-67. PubMed ID: 18282509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic targets in hematopoietic malignancies.
    Claus R; Lübbert M
    Oncogene; 2003 Sep; 22(42):6489-96. PubMed ID: 14528273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eliminating epigenetic barriers induces transient hormone-regulated gene expression in estrogen receptor negative breast cancer cells.
    Fleury L; Gerus M; Lavigne AC; Richard-Foy H; Bystricky K
    Oncogene; 2008 Jul; 27(29):4075-85. PubMed ID: 18317449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coordinated changes in DNA methylation and histone modifications regulate silencing/derepression of luteinizing hormone receptor gene transcription.
    Zhang Y; Fatima N; Dufau ML
    Mol Cell Biol; 2005 Sep; 25(18):7929-39. PubMed ID: 16135786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel approaches on epigenetics.
    Papait R; Monti E; Bonapace IM
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):264-75. PubMed ID: 19333872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic mechanisms in AML - a target for therapy.
    Oki Y; Issa JP
    Cancer Treat Res; 2010; 145():19-40. PubMed ID: 20306243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.